Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

Kyle LaHucik

Associate Editor

Senda Biosciences will look a little different than it did two years ago when Flagship Pioneering unwrapped the bow on the venture, a merger of Senda and Kintai Therapeutics.

Originally home to six preclinical programs with ambitions for treating multiple sclerosis, Parkinson’s, colorectal cancer, chronic kidney disease, obesity and other diseases, the startup is fine-tuning its path and will soon present a clearer scope of its future.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

Two years post-merg­er, Flag­ship’s Sen­da re­fines pipeline and re­plen­ish­es the bank

Kyle LaHucik

Associate Editor

Unlock this article instantly by becoming a free subscriber.

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

Two years post-merger, Flagship’s Senda refines pipeline and replenishes the bank

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...